Zealand Pharma A/S provided earnings guidance for the fiscal year 2022. For the period, the company expects net product revenue from the sales of its commercial products of DKK 235.0 million +/-10% compared to 2021 of DKK 184.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
662.5 DKK | +2.24% | +1.92% | +77.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.52% | 5.92B | |
+18.15% | 124B | |
+18.02% | 112B | |
-12.75% | 22.22B | |
+5.07% | 22.94B | |
-39.94% | 16.87B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Zealand Pharma A/S Provides Earnings Guidance for the Fiscal Year 2022